Texas Liver Institute and University of Texas Health San Antonio, San Antonio, TX. Electronic address: email@example.com.
Texas Liver Institute and University of Texas Health San Antonio, San Antonio, TX.
Gilead Sciences, Inc., Foster City, CA.
University of California at San Diego, San Diego, CA.
University of California Berkeley, Berkeley, CA.
BACKGROUND & AIMS:
Increased de novo lipogenesis (DNL) contributes to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl-CoA carboxylase catalyzes the rate-limiting step in DNL. We evaluated the safety and efficacy of GS 0976, a small molecule inhibitor of acetyl-CoA carboxylase, in patients with NASH.
In an open-label prospective study, patients with NASH (n=10) received GS-0976 20 mg orally once daily for 12 weeks. NASH was diagnosed based on a proton density fat fraction estimated by magnetic resonance imaging (MRI-PDFF) >10% and liver stiffness by magnetic resonance elastography (MRE) >2.88 kPa. The contribution from hepatic DNL to plasma palmitate was measured by 14 days of heavy water labeling before and at the end of treatment. We performed the same labelling protocol in an analysis of healthy volunteers who were not given DNL (controls, n=10). MRI-PDFF and MRE at baseline, and at weeks 4 and 12 of GS-0976 administration, were measured. We analyzed markers of liver injury and serum markers of fibrosis.
The contribution of hepatic DNL to plasma palmitate was significantly greater in patients with NASHcompared with controls (43% vs 18%) (P=.003). After 12 weeks administration of GS-0976, the median hepatic DNL was reduced 22% from baseline in patients with NASH (P=.004). Compared with baseline, reductions in MRI-PDFF at week 12 (15.7% vs 9.1% at baseline ; P=.006), liver stiffness by MRE (3.4 kPa vs 3.1 kPa at baseline ; P=.049), TIMP metallopeptidase inhibitor 1 (275 ng/mL vs 244 ng/mL at baseline ; P=.049), and serum level of alanine aminotransferase (101 U/L vs 57 U/L at baseline ; P=.23) were consistent with decreased hepatic lipid content and liver injury. At week 12, 7 patients (70%) had a ≥30% decrease in MRI-PDFF.
In an open-label study, patients with NASH given GS-0976 for 12 weeks had reduced hepatic DNL, steatosis, and markers of liver injury. ClinicalTrials.gov no: NCT02856555.